Patent ID: 7612168

Claim:
An isolated peptide from HIV-1 Gag p24 protein, which comprises at least one amino acid sequence which contains modifications compared with the native sequence and is selected from the group consisting of: Xaa 1 Xaa 2 Xaa 3 Xaa 4 Xaa 5 Xaa 6 Xaa 7 Gly Xaa 9 Leu Val Xaa 12 Xaa 13 Xaa 14 Tyr Xaa 16 Xaa 17 Xaa 18 Xaa 19 Xaa 20 Xaa 21 Xaa 22 Xaa 23 Ala Xaa 25 Xaa 26 Xaa 27 Xaa 28 (SEQ ID NO: 4), wherein Xaa 1 is Pro, Tyr or Phe, Xaa 2 is Ile, Val or Leu, Xaa 3 is Ile, Leu, Val, Ala or Met, Xaa 4 is Gln, Ser, Thr or Val, Xaa 5 is Asn, Asp or Thr, Xaa 6 is Ile, Ala, Leu or Met, Xaa 7 is Gln, Glu, Lys or Gly, Xaa 9 is Gln or Ile, Xaa 12 is none, Xaa 13 is none, Xaa 14 is none, Xaa 16 is Ala, Ser, Asn, Val or Pro, Xaa 17 is Ile, Leu, Met or Val, Xaa 18 is Ser or Thr, Xaa 19 is Pro or Ala, Xaa 20 is Arg or Lys, Xaa 21 is Thr or Ser, Xaa 22 is Leu or Ser, Xaa 23 is Asn, Phe or Val, Xaa 25 is Trp, Tyr, Gly or none, Xaa 26 is Val, Leu, Gly or none, Xaa 27 is Lys, Arg, Gly or none, Xaa 28 is Val, Ala, Cys, Gly or none; Xaa 1 Ala Xaa 3 Xaa 4 Xaa 5 Ala Xaa 7 Xaa 8 Xaa 9 Leu Leu Xaa 12 Xaa 13 Xaa 14 Xaa 15 Xaa 16 Xaa 17 Xaa 18 Xaa 19 His Gln Xaa 22 Ala Xaa 24 Xaa 25 (SEQ ID NO: 9), wherein Xaa 1 is Tyr, Trp, Phe or Gly, Xaa 3 is Thr, Ala, Val, Ile or Leu, Xaa 4 is Pro or Ser, Xaa 5 is Gln, His, Gly, Thr, Ser or Tyr, Xaa 7 is Leu, Ile or Val, Xaa 8 is Asn or Tyr, Xaa 9 is Thr, Met, Leu or Ala, Xaa 12 is Ser, Thr or Asn, Xaa 13 is Thr, Ile, Val or Ala, Xaa 14 is Val or Ile, Xaa 15 is none, Xaa 16 is none, Xaa 17 is none, Xaa 18 is Gly or none, Xaa 19 is Gly or none, Xaa 22 is Ala or Gly, Xaa 24 is Met, Leu, Cys or none, Xaa 25 is Gln, Glu, His, Gly or none; Xaa 1 Xaa 2 Ala Leu Ala Gly Xaa 7 Xaa 8 Xaa 9 Leu Xaa 11 Xaa 12 Xaa 13 Xaa 14 Xaa 15 Xaa 16 Xaa 17 Xaa 18 Xaa 19 Xaa 20 Xaa 21 (SEQ ID NO: 15), wherein Xaa 1 is Trp or Tyr, Xaa 2 is Ser or Ala, Xaa 7 is Thr, Ala or Ser, Xaa 8 is Ser or Thr, Xaa 9 is Ser or Thr, Xaa 11 is Leu, Pro, Val or Gln, Xaa 12 is Gin, Ala or His, Xaa 13 is Glu or Gly, Xaa 14 is Gin or His, Xaa 15 is Ile, Leu, Val or Met, Xaa 16 is Gly, Ala, Gln, Thr, Asn, Arg, His or Ile, Xaa 17 is Trp or Tyr, Xaa 18 is Thr, Met, Leu or Ile, Xaa 19 is Thr or Ser, Xaa 20 is Cys, Gly or none, Xaa 21 is Gly or none wherein the terminal ends of the sequences may be free carboxyl- or amino groups, amides, acyls, acetyls or salts thereof, two or more of the Cys residues may form part of an interchain disulphide binding, a —S—(CH2) p —S— or a —(CH2) p —-bridge wherein p=1-8 optionally intervened by one or more hetero atoms such as O, N and S and/or the said peptide sequences are immobilized to a solid support.